anti-CD19 CAR T-cell therapy expressing anti-IL6 scFv and IL1RA (Celledit)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD19 CAR T-cell therapy expressing anti-IL6 scFv and IL1RA (Celledit)
Drug Alias NameCD19.CART/IL6/IL1 (Celledit)anti-CD19 CAR T-cell therapy that produce anti-IL6 scFv and IL1RA (Celledit)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-1 receptor antagonistsB-lymphocyte antigen CD19 modulatorsIL-6 receptor antagonists
TargetsB-lymphocyte antigen CD19Interleukin-1 receptorIL-6 receptor
Therapy Area/IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesCelledit Llc
China Registration ClassN/A

Develop Information

Active CompaniesCelledit Llc
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A